Druggability Technologies (DRGT) is a specialty pharmaceutical company dedicated to the development and commercialization of high-value proprietary drugs that deliver measurable and meaningful improvement in clinical utility. This mission is enabled through the deployment of the Company's Super-API drug development platform.
Utilizing its Super-API platform the Company carefully selects and screens drugs and develops their Super-API compositions. The Super-API compositions are protected by global composition of matter IPs.
DRGT’s portfolio is de-risked as Super-API development programs are built-on existing APIs and employ two distinct development strategies:
DRGT is incorporated in Ireland with R&D facilities in Budapest, Hungary.